Who is sponsoring NCT05098236?

NCT05098236 is sponsored by University of Rochester.

What drugs are being tested in NCT05098236?

Interventions in NCT05098236: Training in the Blind Field, Training in the Sighted Field.

What condition does NCT05098236 study?

NCT05098236 studies Vision Loss Partial, Hemianopia, Hemianopia Homonymous, Quadrantanopia, Stroke, Ischemic.

Is NCT05098236 still recruiting?

NCT05098236 is currently completed. Last updated 13 November 2024.

Last reviewed 2024-11-13 · How we verify

NCT05098236

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Visual Retraining on Visual Loss Following Visual Cortical Damage

Completed NA Last updated 13 November 2024

What this trial tests

NA trial testing Training in the Blind Field in Vision Loss Partial in 280 participants. Completed in 4 June 2024.

Timeline

26 September 2003

Primary endpoint
4 June 2024

4 June 2024

Quick facts

Lead sponsor	University of Rochester
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	280
Start date	26 September 2003
Primary completion	4 June 2024
Estimated completion	4 June 2024
Sites	1 location across United States

Drugs / interventions tested

Training in the Blind Field
Training in the Sighted Field

Conditions studied

Vision Loss Partial — all drugs for Vision Loss Partial →
Hemianopia — all drugs for Hemianopia →
Hemianopia Homonymous — all drugs for Hemianopia Homonymous →
Quadrantanopia — all drugs for Quadrantanopia →

Sponsor

University of Rochester

Who can join

Adults 17 to 75, any sex, with Vision Loss Partial or Hemianopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project is intended to collect data using standard clinical tests and psychophysics to quantify the effect of visual cortical damage on the structure of the residual visual system, visual perception, spatial awareness, and brain function. The investigators will also assess the effect of intensive visual retraining on the residual visual system, processing of visual information and the use of such information in real-world situations following damage. This research is intended to improve our understanding of the consequences of permanent visual system damage in humans, of methods that can be used to reverse visual loss, and of brain mechanisms by which visual recovery is achieved.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Vision-related quality of life after unilateral occipital stroke.
Dogra N, Redmond BV, Lilley S, Johnson BA, et al · · 2024 · cited 8× · PMID 38956813 · DOI 10.1002/brb3.3582
MAIA and Humphrey Perimetry Differ in Their Estimation of Homonymous Visual Field Defects.
Redmond BV, Fahrenthold BK, Yang J, Saionz EL, et al · · 2024 · PMID 39541110 · DOI 10.1167/tvst.13.11.15

Verify or expand the search:

Other recruiting trials for Vision Loss Partial

Currently open trials in the same condition.

NCT07134777 — Mechanisms of Visual Restoration After Occipital Stroke · recruiting

Other University of Rochester trials

Trials by the same sponsor.

NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05098236 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rochester
Last refreshed: 13 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05098236.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing